Mizuho raised the firm’s price target on Elevance Health (ELV) to $420 from $342 and keeps an Outperform rating on the shares. The firm adjusted price targets in the healthcare facility and managed care space following an analysis of Medicare Advantage star ratings. The target changes are driven by increased earnings visibility on key issues along with the overall rotation into the healthcare sector, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $395 from $373 at Barclays
- Elevance Health price target raised to $398 from $360 at Guggenheim
- Elevance Health price target raised to $412 from $330 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Trade: White House announces drug pricing deal with Pfizer